<\/strong><\/span><\/h4>\n<\/strong><\/span><\/h4>\nProf. Univ. Dr. Alexandru Oan\u021b\u0103<\/strong><\/span>
Membru \u00een Comitetul de Conducere al Societ\u0103\u0163ii Rom\u00e2ne de Dermatologie (SRD)
Secretar de redac\u0163ie al Revistei Dermatovenerologie \u2013 Revista Societ\u0103\u0163ii Rom\u00e2ne de Dermatologie<\/strong><\/span><\/h4>\n <\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″ locked=”off”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.7″ hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n
Vitiligo – o manifestare secundar\u0103 a tratamentului cu pembrolizumab<\/span>
Autori: A. Oan\u0163\u01031, Smaranda \u0162erean2<\/span><\/p>\n1 Dermamed Bra\u015fov, Rom\u00e2nia
2 Centrul Medical Topmed, T\u00e2rgu Mure\u015f, Rom\u00e2nia
<\/span><\/p>\nVitiligo este o leucodermie circumscris\u0103, adesea familial\u0103, idiopatic\u0103 sau dob\u00e2ndit\u0103, caracterizat\u0103 prin macule acromice, cu peri de obicei decolora\u0163i, care prezint\u0103 uneori la periferie o zon\u0103 hiperpigmentat\u0103, frecvent cu dispozi\u0163ie simetric\u0103. Afec\u021biunea este frecvent asociat\u0103 cu tulbur\u0103ri de origine autoimun\u0103. Caz clinic: pacient \u00een v\u00e2rst\u0103 de 62 de ani cu melanom metastatic av\u00e2nd adenopatie axiliar\u0103 st\u00e2ng\u0103 \u0219i paratraheal\u0103 inferioar\u0103, metabolic activ\u0103. Tratamentul cu pembrolizumab intravenos nu a fost urmat de apari\u021bia unei toxicit\u0103\u021bi, dar a indus apari\u021bia de vitiligo pe pielea p\u0103roas\u0103 a capului. Inhibitorii de checkpoints imunologici (anticorpi monoclonali anti-CTLA-4, anti-PD-1, anti-PD-L1), reprezint\u0103 o nou\u0103 clas\u0103 de medica\u0163ie \u00een terapia cancerului, cu toxicitate \u00een principal imunologic\u0103, mediat\u0103 prin reactivarea \u015fi proliferarea limfocitelor T induse care poate afecta, teoretic, toate organele. Toxicitatea dermatologic\u0103 apare at\u00e2t la anti-PD-1 (nivolumab, pembrolizumab) c\u00e2t \u015fi la anti-CTLA-4 (ipilimumab) indiferent de tipul tumorii tratate. Progresele \u015ftiin\u0163ifice actuale au modificat schemele terapeutice ale melanomului \u015fi altor neoplasme, oferind posibilitatea unei supravie\u0163uiri prelungite. Imunoterapia cu inhibitori ai punctelor de control (check points inhibitors, anticorpi anti-PD1) poate fi o \u0219ans\u0103 la via\u021b\u0103 \u00een melanomul metastatic sau nerezecabil. Adi\u0163ional activit\u0103\u0163ii antitumorale pembrolizumabul activeaz\u0103 mecanisme imune determin\u00e2nd o cre\u015ftere a r\u0103spunsului imun \u00eempotriva func\u0163iilor celulare native, gener\u00e2nd efecte secundare autoimune: exanteme, exanteme maculo-papuloase, prurit \u015fi vitiligo.<\/p>\n
VITILIGO – SECONDARY TO PEMBROLIZUMAB TREATMENT<\/span><\/p>\nVitiligo is a circumscribed leukoderma, often familial, idiopathic or acquired, characterized by achromic spots, usually discolored hairs, which sometimes have a hyperpigmented area at the periphery, usually with a symmetrical arrangement. The condition is often associated with autoimmune disorders. Clinical case: 62-year-old patient with metastatic melanoma with left axillary adenopathy and lower paratracheal, metabolically active. Intravenous pembrolizumab treatment was not followed by toxicity, but induced vitiligo on the scalp. Immunological checkpoint inhibitors (anti-CTLA-4, anti-PD-1, anti-PD-L1 monoclonal antibodies) represent a new class of medication in cancer therapy, with mainly immunological toxicity, mediated by the reactivation and proliferation of induced T lymphocytes. which can theoretically affect all organs. Dermatological toxicity occurs with both anti-PD-1 (nivolumab, pembrolizumab) and anti-CTLA-4 (ipilimumab) regardless of the type of tumor being treated. Current scientific advances have altered the therapeutic regimens of melanoma and other neoplasms, offering the possibility of prolonged survival. Immunotherapy with check points inhibitors (anti-PD1 antibodies) may be a chance at life in metastatic or unresectable melanoma. In addition to its antitumor activity, pembrolizumab activates immune mechanisms causing an increase in the immune response against native cellular functions, generating autoimmune side effects: rash, maculo-papular rash, pruritus and vitiligo.<\/p>\n
Scurt CV<\/span><\/p>\n\u2022 Medic primar \u00een specialitatea dermato-venerologie
\u2022 Doctor \u00een \u015etiin\u0163e Medicale
\u2022 Coordonator al Centrului de dermato-venerologie Dermamed Bra\u015fov
\u2022 Membru \u00een Comitetul de Conducere al Societ\u0103\u0163ii Rom\u00e2ne de Dermatologie (SRD)
\u2022 Secretar de redac\u0163ie al Revistei Dermatovenerologie \u2013 Revista Societ\u0103\u0163ii Rom\u00e2ne de Dermatologie
\u2022 Membru fondator al Societ\u0103\u0163ii Rom\u00e2ne de Dermato-Oncologie (SRDO)
\u2022 Membru \u00een Consiliul de Conducere al Asocia\u0163iei Dermatologilor Transilvani (ADT)
\u2022 Membru al Asocia\u0163iei Dermatologilor din Moldova (ADEM)
\u2022 Membru al Societ\u0103\u0163ii Maghiare de Dermato-Venerologie – Magyar dermatol\u00f3giai t\u00e1rsulat (MDT)
\u2022 Membrul al Academiei Europene de Dermatologie \u015fi Venerologie (EADV)
<\/span><\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2021\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.9.4″ title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n
![\"\"](\"https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2020\/02\/eventer_logo_150px.png\")
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n
Parteneri Media<\/p>\n
[\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,9252,9464″ fullwidth=”on” _builder_version=”4.9.6″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Prof. Univ. Dr. Alexandru Oan\u021b\u0103Membru \u00een Comitetul de Conducere al Societ\u0103\u0163ii Rom\u00e2ne de Dermatologie (SRD)Secretar de redac\u0163ie al Revistei Dermatovenerologie \u2013 Revista Societ\u0103\u0163ii Rom\u00e2ne de Dermatologie Vitiligo – o manifestare secundar\u0103 a tratamentului cu pembrolizumab Autori: A. Oan\u0163\u01031, Smaranda \u0162erean2 1 Dermamed Bra\u015fov, Rom\u00e2nia2 Centrul Medical Topmed, T\u00e2rgu Mure\u015f, Rom\u00e2nia Vitiligo este o leucodermie circumscris\u0103, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-9906","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/comments?post=9906"}],"version-history":[{"count":2,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9906\/revisions"}],"predecessor-version":[{"id":9912,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9906\/revisions\/9912"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/media?parent=9906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Prof. Univ. Dr. Alexandru Oan\u021b\u0103<\/strong><\/span>
Membru \u00een Comitetul de Conducere al Societ\u0103\u0163ii Rom\u00e2ne de Dermatologie (SRD)
Secretar de redac\u0163ie al Revistei Dermatovenerologie \u2013 Revista Societ\u0103\u0163ii Rom\u00e2ne de Dermatologie<\/strong><\/span><\/h4>\n <\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″ locked=”off”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.7″ hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n
Vitiligo – o manifestare secundar\u0103 a tratamentului cu pembrolizumab<\/span>
Autori: A. Oan\u0163\u01031, Smaranda \u0162erean2<\/span><\/p>\n1 Dermamed Bra\u015fov, Rom\u00e2nia
2 Centrul Medical Topmed, T\u00e2rgu Mure\u015f, Rom\u00e2nia
<\/span><\/p>\nVitiligo este o leucodermie circumscris\u0103, adesea familial\u0103, idiopatic\u0103 sau dob\u00e2ndit\u0103, caracterizat\u0103 prin macule acromice, cu peri de obicei decolora\u0163i, care prezint\u0103 uneori la periferie o zon\u0103 hiperpigmentat\u0103, frecvent cu dispozi\u0163ie simetric\u0103. Afec\u021biunea este frecvent asociat\u0103 cu tulbur\u0103ri de origine autoimun\u0103. Caz clinic: pacient \u00een v\u00e2rst\u0103 de 62 de ani cu melanom metastatic av\u00e2nd adenopatie axiliar\u0103 st\u00e2ng\u0103 \u0219i paratraheal\u0103 inferioar\u0103, metabolic activ\u0103. Tratamentul cu pembrolizumab intravenos nu a fost urmat de apari\u021bia unei toxicit\u0103\u021bi, dar a indus apari\u021bia de vitiligo pe pielea p\u0103roas\u0103 a capului. Inhibitorii de checkpoints imunologici (anticorpi monoclonali anti-CTLA-4, anti-PD-1, anti-PD-L1), reprezint\u0103 o nou\u0103 clas\u0103 de medica\u0163ie \u00een terapia cancerului, cu toxicitate \u00een principal imunologic\u0103, mediat\u0103 prin reactivarea \u015fi proliferarea limfocitelor T induse care poate afecta, teoretic, toate organele. Toxicitatea dermatologic\u0103 apare at\u00e2t la anti-PD-1 (nivolumab, pembrolizumab) c\u00e2t \u015fi la anti-CTLA-4 (ipilimumab) indiferent de tipul tumorii tratate. Progresele \u015ftiin\u0163ifice actuale au modificat schemele terapeutice ale melanomului \u015fi altor neoplasme, oferind posibilitatea unei supravie\u0163uiri prelungite. Imunoterapia cu inhibitori ai punctelor de control (check points inhibitors, anticorpi anti-PD1) poate fi o \u0219ans\u0103 la via\u021b\u0103 \u00een melanomul metastatic sau nerezecabil. Adi\u0163ional activit\u0103\u0163ii antitumorale pembrolizumabul activeaz\u0103 mecanisme imune determin\u00e2nd o cre\u015ftere a r\u0103spunsului imun \u00eempotriva func\u0163iilor celulare native, gener\u00e2nd efecte secundare autoimune: exanteme, exanteme maculo-papuloase, prurit \u015fi vitiligo.<\/p>\n
VITILIGO – SECONDARY TO PEMBROLIZUMAB TREATMENT<\/span><\/p>\nVitiligo is a circumscribed leukoderma, often familial, idiopathic or acquired, characterized by achromic spots, usually discolored hairs, which sometimes have a hyperpigmented area at the periphery, usually with a symmetrical arrangement. The condition is often associated with autoimmune disorders. Clinical case: 62-year-old patient with metastatic melanoma with left axillary adenopathy and lower paratracheal, metabolically active. Intravenous pembrolizumab treatment was not followed by toxicity, but induced vitiligo on the scalp. Immunological checkpoint inhibitors (anti-CTLA-4, anti-PD-1, anti-PD-L1 monoclonal antibodies) represent a new class of medication in cancer therapy, with mainly immunological toxicity, mediated by the reactivation and proliferation of induced T lymphocytes. which can theoretically affect all organs. Dermatological toxicity occurs with both anti-PD-1 (nivolumab, pembrolizumab) and anti-CTLA-4 (ipilimumab) regardless of the type of tumor being treated. Current scientific advances have altered the therapeutic regimens of melanoma and other neoplasms, offering the possibility of prolonged survival. Immunotherapy with check points inhibitors (anti-PD1 antibodies) may be a chance at life in metastatic or unresectable melanoma. In addition to its antitumor activity, pembrolizumab activates immune mechanisms causing an increase in the immune response against native cellular functions, generating autoimmune side effects: rash, maculo-papular rash, pruritus and vitiligo.<\/p>\n
Scurt CV<\/span><\/p>\n\u2022 Medic primar \u00een specialitatea dermato-venerologie
\u2022 Doctor \u00een \u015etiin\u0163e Medicale
\u2022 Coordonator al Centrului de dermato-venerologie Dermamed Bra\u015fov
\u2022 Membru \u00een Comitetul de Conducere al Societ\u0103\u0163ii Rom\u00e2ne de Dermatologie (SRD)
\u2022 Secretar de redac\u0163ie al Revistei Dermatovenerologie \u2013 Revista Societ\u0103\u0163ii Rom\u00e2ne de Dermatologie
\u2022 Membru fondator al Societ\u0103\u0163ii Rom\u00e2ne de Dermato-Oncologie (SRDO)
\u2022 Membru \u00een Consiliul de Conducere al Asocia\u0163iei Dermatologilor Transilvani (ADT)
\u2022 Membru al Asocia\u0163iei Dermatologilor din Moldova (ADEM)
\u2022 Membru al Societ\u0103\u0163ii Maghiare de Dermato-Venerologie – Magyar dermatol\u00f3giai t\u00e1rsulat (MDT)
\u2022 Membrul al Academiei Europene de Dermatologie \u015fi Venerologie (EADV)
<\/span><\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2021\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.9.4″ title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n
Parteneri Media<\/p>\n
[\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,9252,9464″ fullwidth=”on” _builder_version=”4.9.6″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Prof. Univ. Dr. Alexandru Oan\u021b\u0103Membru \u00een Comitetul de Conducere al Societ\u0103\u0163ii Rom\u00e2ne de Dermatologie (SRD)Secretar de redac\u0163ie al Revistei Dermatovenerologie \u2013 Revista Societ\u0103\u0163ii Rom\u00e2ne de Dermatologie Vitiligo – o manifestare secundar\u0103 a tratamentului cu pembrolizumab Autori: A. Oan\u0163\u01031, Smaranda \u0162erean2 1 Dermamed Bra\u015fov, Rom\u00e2nia2 Centrul Medical Topmed, T\u00e2rgu Mure\u015f, Rom\u00e2nia Vitiligo este o leucodermie circumscris\u0103, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-9906","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/comments?post=9906"}],"version-history":[{"count":2,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9906\/revisions"}],"predecessor-version":[{"id":9912,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9906\/revisions\/9912"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/media?parent=9906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Autori: A. Oan\u0163\u01031, Smaranda \u0162erean2<\/span><\/p>\n
1 Dermamed Bra\u015fov, Rom\u00e2nia Vitiligo este o leucodermie circumscris\u0103, adesea familial\u0103, idiopatic\u0103 sau dob\u00e2ndit\u0103, caracterizat\u0103 prin macule acromice, cu peri de obicei decolora\u0163i, care prezint\u0103 uneori la periferie o zon\u0103 hiperpigmentat\u0103, frecvent cu dispozi\u0163ie simetric\u0103. Afec\u021biunea este frecvent asociat\u0103 cu tulbur\u0103ri de origine autoimun\u0103. Caz clinic: pacient \u00een v\u00e2rst\u0103 de 62 de ani cu melanom metastatic av\u00e2nd adenopatie axiliar\u0103 st\u00e2ng\u0103 \u0219i paratraheal\u0103 inferioar\u0103, metabolic activ\u0103. Tratamentul cu pembrolizumab intravenos nu a fost urmat de apari\u021bia unei toxicit\u0103\u021bi, dar a indus apari\u021bia de vitiligo pe pielea p\u0103roas\u0103 a capului. Inhibitorii de checkpoints imunologici (anticorpi monoclonali anti-CTLA-4, anti-PD-1, anti-PD-L1), reprezint\u0103 o nou\u0103 clas\u0103 de medica\u0163ie \u00een terapia cancerului, cu toxicitate \u00een principal imunologic\u0103, mediat\u0103 prin reactivarea \u015fi proliferarea limfocitelor T induse care poate afecta, teoretic, toate organele. Toxicitatea dermatologic\u0103 apare at\u00e2t la anti-PD-1 (nivolumab, pembrolizumab) c\u00e2t \u015fi la anti-CTLA-4 (ipilimumab) indiferent de tipul tumorii tratate. Progresele \u015ftiin\u0163ifice actuale au modificat schemele terapeutice ale melanomului \u015fi altor neoplasme, oferind posibilitatea unei supravie\u0163uiri prelungite. Imunoterapia cu inhibitori ai punctelor de control (check points inhibitors, anticorpi anti-PD1) poate fi o \u0219ans\u0103 la via\u021b\u0103 \u00een melanomul metastatic sau nerezecabil. Adi\u0163ional activit\u0103\u0163ii antitumorale pembrolizumabul activeaz\u0103 mecanisme imune determin\u00e2nd o cre\u015ftere a r\u0103spunsului imun \u00eempotriva func\u0163iilor celulare native, gener\u00e2nd efecte secundare autoimune: exanteme, exanteme maculo-papuloase, prurit \u015fi vitiligo.<\/p>\n VITILIGO – SECONDARY TO PEMBROLIZUMAB TREATMENT<\/span><\/p>\n Vitiligo is a circumscribed leukoderma, often familial, idiopathic or acquired, characterized by achromic spots, usually discolored hairs, which sometimes have a hyperpigmented area at the periphery, usually with a symmetrical arrangement. The condition is often associated with autoimmune disorders. Clinical case: 62-year-old patient with metastatic melanoma with left axillary adenopathy and lower paratracheal, metabolically active. Intravenous pembrolizumab treatment was not followed by toxicity, but induced vitiligo on the scalp. Immunological checkpoint inhibitors (anti-CTLA-4, anti-PD-1, anti-PD-L1 monoclonal antibodies) represent a new class of medication in cancer therapy, with mainly immunological toxicity, mediated by the reactivation and proliferation of induced T lymphocytes. which can theoretically affect all organs. Dermatological toxicity occurs with both anti-PD-1 (nivolumab, pembrolizumab) and anti-CTLA-4 (ipilimumab) regardless of the type of tumor being treated. Current scientific advances have altered the therapeutic regimens of melanoma and other neoplasms, offering the possibility of prolonged survival. Immunotherapy with check points inhibitors (anti-PD1 antibodies) may be a chance at life in metastatic or unresectable melanoma. In addition to its antitumor activity, pembrolizumab activates immune mechanisms causing an increase in the immune response against native cellular functions, generating autoimmune side effects: rash, maculo-papular rash, pruritus and vitiligo.<\/p>\n Scurt CV<\/span><\/p>\n \u2022 Medic primar \u00een specialitatea dermato-venerologie [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\n Contacteaz\u0103 operatorul PDI 2021<\/p>\n [\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2021\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.9.4″ title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n Operatorul PDI 2021<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n <\/span><\/p>\n <\/span><\/p>\n Adresa: Str. A. Panu nr. 13, Iasi<\/span> [\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n Parteneri Media<\/p>\n [\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,9252,9464″ fullwidth=”on” _builder_version=”4.9.6″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" Prof. Univ. Dr. Alexandru Oan\u021b\u0103Membru \u00een Comitetul de Conducere al Societ\u0103\u0163ii Rom\u00e2ne de Dermatologie (SRD)Secretar de redac\u0163ie al Revistei Dermatovenerologie \u2013 Revista Societ\u0103\u0163ii Rom\u00e2ne de Dermatologie Vitiligo – o manifestare secundar\u0103 a tratamentului cu pembrolizumab Autori: A. Oan\u0163\u01031, Smaranda \u0162erean2 1 Dermamed Bra\u015fov, Rom\u00e2nia2 Centrul Medical Topmed, T\u00e2rgu Mure\u015f, Rom\u00e2nia Vitiligo este o leucodermie circumscris\u0103, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-9906","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/comments?post=9906"}],"version-history":[{"count":2,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9906\/revisions"}],"predecessor-version":[{"id":9912,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9906\/revisions\/9912"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/media?parent=9906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
2 Centrul Medical Topmed, T\u00e2rgu Mure\u015f, Rom\u00e2nia
<\/span><\/p>\n
\u2022 Doctor \u00een \u015etiin\u0163e Medicale
\u2022 Coordonator al Centrului de dermato-venerologie Dermamed Bra\u015fov
\u2022 Membru \u00een Comitetul de Conducere al Societ\u0103\u0163ii Rom\u00e2ne de Dermatologie (SRD)
\u2022 Secretar de redac\u0163ie al Revistei Dermatovenerologie \u2013 Revista Societ\u0103\u0163ii Rom\u00e2ne de Dermatologie
\u2022 Membru fondator al Societ\u0103\u0163ii Rom\u00e2ne de Dermato-Oncologie (SRDO)
\u2022 Membru \u00een Consiliul de Conducere al Asocia\u0163iei Dermatologilor Transilvani (ADT)
\u2022 Membru al Asocia\u0163iei Dermatologilor din Moldova (ADEM)
\u2022 Membru al Societ\u0103\u0163ii Maghiare de Dermato-Venerologie – Magyar dermatol\u00f3giai t\u00e1rsulat (MDT)
\u2022 Membrul al Academiei Europene de Dermatologie \u015fi Venerologie (EADV)
<\/span><\/p>\n<\/span><\/p>\n
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n